StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research report released on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.
Evogene Stock Performance
Shares of EVGN opened at $1.60 on Monday. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.40. The stock has a fifty day moving average of $1.61 and a two-hundred day moving average of $3.00. The company has a market capitalization of $8.58 million, a PE ratio of -0.36 and a beta of 1.30.
Hedge Funds Weigh In On Evogene
An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- When to Sell a Stock for Profit or Loss
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- How Do Stock Buybacks Affect Shareholders?
- What is the Hang Seng index?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
